- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04029883
Behavioral Economics to Improve Antihypertensive Therapy Adherence (BETA)
Behavioral Economics to Improve Antihypertensive Therapy Adherence (BETA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators propose to complement linking medication taking to a daily routine with two added components to make it easier for participants to stick to their anchoring plan: increasing information salience through frequent text messages and providing intermittent rewards for pill-taking according to the anchoring plan.
This study will be implemented in a pilot randomized controlled trial (RCT) in a high-volume clinical practice to establish feasibility, acceptability, and preliminary efficacy. The specific aims include 1) a formative phase to develop the intervention and evaluate its feasibility and acceptability via focus groups with key stakeholders; 2) a RCT of 60 hypertensive patients in which a control group (n=20) is provided education on anchoring medication taking to a daily routine, and two intervention groups, one (n=20) who receives anchoring education and daily text message reminders and another (n=20) which receives anchoring education, text messages, and financial incentives for adherence in accordance with their anchoring plan; and 3) data collection in preparation for a future R01 application, including focus group discussions with key stakeholders (patients, providers [Physicians, Nurses, Advanced Care Practitioners, Pharmacists] and clinic staff) and exit focus groups with study participants regarding ways to improve the intervention.
The main hypothesis is: the intervention is effective by anchoring pill-taking to an existing routine, tested by comparing the pooled (Message group + Incentive group) vs. the Control group. The secondary hypothesis is: adding incentives to the text messages is more effective for routinizing pill-taking (testing outcomes in the Incentive group vs. Message group). Outcomes from this study have the potential to greatly enhance our understanding of the barriers and facilitators of medication adherence among hypertensive patients and potentially provide evidence for a low-cost and scalable intervention to improve medication adherence in clinical practice.
This pilot RCT will also include a smaller pilot of a novel data collection method, video diaries, using the Medallia Living Lens platform. A convenience sample of 30 participants (10 from each group) will be consented and enrolled, and will be asked to upload a short video in response to structured prompts once a week for three weeks. The prompts will be geared towards experiences with the study design and interventions, and the data collected will be analyzed using the Living Lens platform.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- 18 years or older
- On anti-hypertensive medication (AH)
- Own, or have access to a phone at least five days a week throughout the duration of the intervention,
- Willing to receive study text messages
Exclusion criteria:
- Under 18 years of age
- Not approved to participate by their provider
- Not willing to use MEMS caps
- Not mentally fit to provide voluntary consent
- Already enrolled in another comparable study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control Group
The Control group will receive care as usual, as well as a MEMS-cap and a leaflet explaining the importance of pill-taking routines and how to establish them.
The study coordinator will spend approximately ten minutes with them to go over the leaflet and answer questions.
Control group participants also spend time with the study coordinator at each clinic visit where contact information is updated, and any MEMS-cap problems are resolved.
These procedures, which we successfully applied in previous studies, minimize the possibility that results are confounded by differences in attention or other non-specific effects between groups.
|
|
Active Comparator: Message Group
The Message group will receive the same brief information session as the Control group but also receive daily text messages reinforcing the information provided for 3 months.
A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.
To keep the importance of routinizing pill- taking salient (i.e.
high on a person's mental priority list), we will send daily text messages using a freely available web platform.
These messages will reinforce the information provided at recruitment, and remind participants of their personalized routinization strategy.
Messages will be tailored and refreshed based on patient-specific factors including BP control, prior adherence, and current medication regimen.
|
A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103
To keep the importance of routinizing pill-taking salient (i.e.
high on a person's mental priority list), we will send daily text messages using a freely available web platform.
|
Experimental: Incentive Group
The Incentive group will receive the same information and text messages, but in addition have a chance of winning small, intermittent rewards for taking their medication at the time coinciding with their anchoring strategy.
In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits.
When the participants return for their monthly visit, the study coordinator will download their MEMS-cap data and check whether this eligibility criteria was satisfied.
MEMS software can be easily customized to display this information.
If the patient qualifies, s/he is invited to draw one of three laminated cards with numbers 0, 25, and 50 out of a bag.
The client receives the corresponding amount in USD in the form of a gift card immediately after the drawing.
|
A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103
To keep the importance of routinizing pill-taking salient (i.e.
high on a person's mental priority list), we will send daily text messages using a freely available web platform.
In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electronically Measured Mean Medication Adherence During Intervention
Time Frame: 3 months
|
The MEMS-data collected continuously over the course of the three-month intervention period will be used to calculate the primary adherence variable, which is defined as the percentage of timely (within 1 hour of anchor time) actual bottle openings out of the total number of prescribed bottle openings (# of actual once-a-day bottle openings within 1 hour of anchor time during the intervention period / # of prescribed once-a-day bottle openings during the intervention period).
Only one of the anti-hypertension (AH) medications will be used to measure adherence
|
3 months
|
Electronically Measured Mean Medication Adherence Post Intervention
Time Frame: 6 months post intervention
|
MEMS data will also be collected continuously over the six-month post intervention period.
These data will be used to evaluate the post-intervention mean adherence, whose definition is identical to the primary outcome 1: ratio of the number of actual bottle openings to the prescribed bottle openings.
|
6 months post intervention
|
Routinization of AH Adherence Post-intervention
Time Frame: 6 months post intervention
|
This measure would be calculated as the fraction of scheduled pills taken within a one-hour window around the typical time that participants report completing their existing routine behavior that anchors their pill-taking, for all visits made post-intervention.
|
6 months post intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hypertension Control
Time Frame: 3 months and 9 months
|
This is a reliable biological measure of AH adherence since controlled blood pressure is correlated with high AH medication adherence.
This measure will be defined as a binary variable indicating whether or not the blood pressure measured was < 130/80 mmHg.
The measure will be calculated for two time periods: at the end of the intervention and at the end of the post-intervention period.
|
3 months and 9 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00057764
- 1R21HL156132-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Text Message
-
University of California, San FranciscoUniversity of WashingtonCompleted
-
University of WashingtonUniversity of Illinois at Chicago; Kenya Medical Research InstituteCompletedHIV Infections | Acquired Immunodeficiency Syndrome | Circumcision, Male | Patient Compliance | Cellular PhoneKenya
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
Texas Tech University Health Sciences CenterTexas Tech UniversityCompletedBreast Cancer FemaleUnited States
-
University of WashingtonUniversity of California, San Francisco; Kenya Medical Research InstituteCompletedHIV Infections | Acquired Immunodeficiency SyndromeKenya
-
Jonsson Comprehensive Cancer CentereHealth International, INC.RecruitingObesity | Malignant NeoplasmUnited States
-
Wake Forest University Health SciencesCompleted
-
New York City Health and Hospitals CorporationWithdrawn
-
Columbia UniversityPfizerCompletedVaccinationUnited States
-
University of PittsburghCompleted